The Association between Nonalcoholic Fatty Liver Disease and Stroke: Results from the Korean Genome and Epidemiology Study (KoGES)

Yun-Jung Yang 1,†, Mi-Hyang Jung 2,†, Seok-Hoo Jeong 3,†, Yeon-Pyo Hong 4, Yeon In Kim 5 and Sang Joon An 5,*

1 Institute of Biomedical Science, Catholic Kwandong University International St. Mary’s Hospital, Incheon 22711, Korea; yangyj@ish.ac.kr
2 Cardiovascular Center, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong-Si 18450, Korea; flora0515@gmail.com
3 Division of Gastroenterology, Department of Internal Medicine, Catholic Kwandong University International St. Mary’s Hospital, Incheon 22711, Korea; ssukoo@naver.com
4 Department of Preventive Medicine, College of Medicine, Chung-Ang University, Seoul 06974, Korea; hyp026@cau.ac.kr
5 Department of Neurology, Catholic Kwandong University International St. Mary’s Hospital, Incheon 22711, Korea; nuyikim@ish.ac.kr
* Correspondence: neuroan@gmail.com or neuroan@cku.ac.kr; Tel.: +82-32-290-2994; Fax: +82-32-290-3879
† Yun-Jung Yang and Mi-Hyang Jung contributed equally to this work.

Received: 2 December 2020; Accepted: 16 December 2020; Published: 21 December 2020

Abstract: (1) Background: Non-alcoholic fatty liver disease (NAFLD) is associated with various cardiometabolic diseases. However, the association between NAFLD and stroke is not well known. The purpose of our study is to reveal the relationship between NAFLD and Stroke incidence. (2) Methods: Using data from a Korean prospective cohort study, we excluded participants with heavy alcohol consumption and a history of stroke; hence, 7964 adults aged 40–69 years were included in this study. According to their fatty liver index (FLI), participants were divided into three groups: <30 (n = 4550, non-NAFLD), 30–59.9 (n = 2229, intermediate), and ≥60 (n = 1185, NAFLD). The incidence of stroke according to the degree of FLI was evaluated using the Cox proportional hazard model. (3) Results: During the 12-year follow-up period, 168 strokes occurred. A graded association between NAFLD and stroke incidence was observed, i.e., 1.7% (n = 76), 2.5% (n = 56), and 3.0% (n = 36) for non-NAFLD, intermediate, and NAFLD FLI groups, respectively. After adjusting for confounding variables and compared to the risk of stroke in the non-NAFLD group, the risk of stroke in the NAFLD group was the highest (hazard ratio [HR]: 1.98, 95% confidence interval [CI]: 1.17–3.34), followed by the risk of stroke in the intermediate group (HR: 1.41, 95% CI: 0.94–2.21) (p for trend < 0.001). However, the level of aspartate aminotransferase, alanine aminotransferase, or gamma-glutamyltransferase alone did not show any significant association with stroke. (4) Conclusions: This study demonstrated that the risk of stroke incidence gradually increased with the degree of FLI. Individuals with NAFLD should be properly counseled and monitored for risk for stroke.

Keywords: stroke; non-alcoholic fatty liver disease; incidence; risk factors; liver; cohort studies
1. Introduction

Stroke is a significant health burden worldwide [1–3]. The prevalence of stroke, the third-largest cause of death in Korea, is increasing rapidly [4]. Every year, there are 105,000 new or recurrent stroke cases in Korea. An average of one new stroke occurs every 5 min [5]. Stroke is a heterogeneous disease arising from several distinct underlying pathologies [6]. Therefore, the mechanisms and risk factors of stroke vary widely. Classical risk factors include nonmodifiable characteristics, such as age and ethnicity, and modifiable risk factors, such as coronary heart disease, atrial fibrillation, diabetes mellitus, hypertension, smoking, dyslipidemia, and obesity [7,8].

Non-alcoholic fatty liver disease (NAFLD) is characterized by the presence of significant lipid accumulation in the liver parenchyma without excessive alcohol ingestion or any other liver disease [9]. NAFLD is the most common chronic liver disease and affects approximately 34–46% of the population [10]. NAFLD has been known to be associated with various cardiovascular diseases, including type 2 diabetes mellitus and obesity, and emerging risk factors related to subclinical atherosclerosis and reduced adiponectin levels [11]. However, the role of NAFLD in stroke is not conclusive and results have varied across studies [12–15]. Currently, limited data are available for many Asians including Koreans [16]. Moreover, Asians have different stroke characteristics from Western populations with a higher prevalence of hemorrhagic stroke than ischemic stroke [7] and different metabolic profiles with worse insulin resistance and more body fat with the same body mass index [17]. Previous data estimating the role of NAFLD in stroke risk are inconsistent and inconclusive, probably because of the diverse study populations [18]. Therefore, this study aimed to characterize the role of NAFLD in the risk of stroke in middle-aged adults based on a prospective cohort study in Korea.

2. Materials and Methods

2.1. Study Subjects

This study used data from the Ansung–Ansan cohort, which is part of the Korean Genome and Epidemiology Study (KoGES). The design and survey methods of the KoGES have been previously described [19]. Briefly, the Ansung–Ansan cohort has existed since 2001 including 10,030 adults aged 40 to 69 living in the area. They have undergone face-to-face surveys and physical examinations. The details of this cohort have been described in a previous study [19].

Participants with missing data regarding the diagnosis of cerebrovascular disease (n = 4), alcohol consumption (n = 305), smoking status (n = 66), triglyceride, aspartate aminotransferase (AST), alanine aminotransferase (ALT), body weight and waist circumstance (n = 17) were excluded. Subjects with pre-existing cerebrovascular disease (n = 112; 60 men, 52 women) were further excluded. Among the remaining subjects, 1562 were excluded because of AST/ALT ratio > 2, as this can be an indicator of alcoholic liver disease (n = 254), self-reported history of hepatitis (n = 384), or alcohol intake amount >30 g/day in men and >20 g/day in women (n = 845 men and n = 79 women). Finally, 7964 participants (3312 men and 4652 women) were included in this analysis (Figure 1). The study protocol was approved by the Korea Centers for Disease Control and Prevention Institutional Review Board and by the Institute Review Board at the Catholic Kwandong University International St. Mary’s Hospital (IS18EISI0071).
2.2. Data Collection

The demographic and behavioral information including age, sex, physical activity, smoking and drinking status, medical history, and the use of medication was obtained from a face-to-face survey performed by a trained interviewer. Age was divided into two groups based on the population median. Smoking and alcohol status was classified as never, former, and current. The intensity of physical activity was categorized according to the quartile of the metabolic equivalent of task (MET) values. Cancer was defined as a self-reported history of lung cancer, stomach cancer, liver cancer, colon cancer, pancreatic cancer, uterine cancer, breast cancer, thyroid cancer, prostate cancer, or gallbladder cancer.

Bodyweight, height, and waist circumstance were measured following the standard methods. Body mass index (BMI, kg/m²) was calculated as body weight divided by height squared. BMI was classified as normal and obese according to the World Health Organization cut-off values for Asian adults: normal weight as BMI 18.5–24.9 kg/m², underweight as BMI < 18.5 kg/m², moderate obesity as BMI 25.0–29.9 kg/m², and severe obesity as BMI ≥ 30 kg/m². Hypertension was defined as self-reported history of hypertension, use of antihypertensive drugs, or systolic blood pressure ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg. Diabetes mellitus was defined as a self-reported history of diabetes mellitus, use of the antidiabetic drug, or fasting glucose level ≥ 126 mg/dL.
Hyperlipidemia was defined as a self-reported history of hyperlipidemia, use of anti-hyperlipidemia drug, triglyceride $\geq$ 240 mg/dL, high-density lipoprotein cholesterol $\leq$ 40 mg/dL, or low-density lipoprotein cholesterol $\geq$ 160 mg/dL. Cardiovascular disease was defined as a self-reported history of cardiovascular disease. The use of anti-hyperlipidemia drug was defined as past or current use of an anti-hyperlipidemia drug in self-reported history. The occurrence of stroke was determined using a questionnaire that asked participants whether they had ever been diagnosed with a stroke by a doctor. Stroke subtype (e.g., ischemic, hemorrhagic) was not specified in the questionnaire. Data of the following biochemical parameters were collected: serum triglyceride (TG), gamma-glutamyltransferase (GGT), ALT, and AST.

2.3. Measurement of Fatty Liver Index (FLI) and Definition of NAFLD

The FLI was calculated to determine the NAFLD status. BMI, GGT, waist circumstance, and triglycerides were used to calculate FLI according to the following formula:

$$\text{FLI} = \frac{e^{0.953\times \log(TG)+0.139\times \text{BMI}+0.718\times \log(GGT)+0.053\times \text{waist circumference}}-15.745}{1-e^{0.953\times \log(TG)+0.139\times \text{BMI}+0.718\times \log(GGT)+0.053\times \text{waist circumference}}-15.745} \times 100$$

with TG measured in mmol/L, GGT in U/L, and waist circumference in ftcm. According to a previous study [20], FLI $\geq$ 60 was considered as representative of liver steatosis.

Subjects were classified into three groups based on the FLI score; FLI $< 30$ was defined as non-NAFLD, FLI 30–59.9 was defined as intermediate, and FLI $\geq 60$ was defined as NAFLD.

2.4. Statistical Analysis

Data are expressed as the mean and standard error (continuous) or as frequencies and percentages (categorical). Comparisons between groups were performed using the t-test (continuous variable) or $\chi^2$ test (categorical). Survival time was defined as the time between the baseline and onset of the outcome or final follow-up. Patients who were lost to follow-up or had died were censored. The Cox proportional hazard model was used to estimate the association between FLI and incidence of stroke after adjustment for confounding variables. The incidence time was calculated by subtracting the date of initial participation from the final participation date. Multivariate analysis adjusted for FLI, age, sex, and comorbidities with robust sandwich estimators. Model 1 either adjusted for or was stratified by non-modifiable risk factors such as age and sex. Model 2 was additionally adjusted for well-known and proven modifiable risk factors such as hypertension, diabetes mellitus, hyperlipidemia, cardiovascular disease, smoking, alcohol status, and body mass index. Model 3 was additionally adjusted for other factors such as the metabolic equivalent of task, cancer, hyperlipidemia drug, and antihypertension drug. Analyzed results are expressed as hazard ratio (HR) and 95% confidence interval (CI). Data analysis was performed using STATA (version 15.0 StataCorp LP, College Station, TX, USA). $p$-values less than 0.05 were considered significant.

3. Results

3.1. Baseline Characteristics

The baseline characteristics of participants grouped according to their FLI scores are shown in Table 1. This study included 4550, 2229, and 1185 participants in the non-NAFLD, intermediate, and NAFLD groups, respectively, and the mean ± standard error age was 51.67 ± 0.13, 53.86 ± 0.18, and 53.06 ± 0.25 years, respectively. Men were more predominant in the NAFLD group ($n = 708, 59.75\%$) than in the intermediate ($n = 1043, 46.79\%$) and non-NAFLD ($n = 1056, 34.3\%$) groups. Moreover, compared with participants in the non-NAFLD and intermediate groups, participants in the NAFLD group had higher alcohol consumption ($n = 614, 51.8\%$) and smoking ($n = 378, 31.0\%$) rates and incidences of hypertension ($n = 716, 60.4\%$), diabetes mellitus ($n = 200, 16.9\%$), hyperlipidemia ($n = 859, 72.5\%$) as well as a higher BMI (28.05 ± 0.09) (all $p < 0.001$).
Table 1. Baseline characteristics of the study participants according to fatty liver index (FLI) score.

| Variables                  | FLI Score | p-Value |
|----------------------------|-----------|---------|
|                            | <30       | 30–59   | ≥60     |
| Participants, n            | 4550      | 2229    | 1185    | <0.001  |
| Gender, n (%)              |           |         |         |
| Men                        | 1561 (34.3) | 1043 (46.79) | 708 (59.75) | <0.001  |
| Women                      | 2989 (65.7) | 1186 (53.21) | 477 (40.25) |
| Age, y                     | 51.67 ± 0.13 | 53.86 ± 0.18 | 53.06 ± 0.25 | <0.001  |
| BMI, kg/m²                 | 23.04 ± 0.04 | 26.02 ± 0.04 | 28.05 ± 0.09 | <0.001  |
| Drinking Status, n(%)     |           |         |         |
| Never                      | 2615 (57.5) | 1131 (50.7) | 469 (39.6) | <0.001  |
| Former                     | 287 (6.3)  | 189 (8.5)  | 102 (8.6)  |
| Current                    | 1648 (36.2) | 909 (40.8) | 614 (51.8) |
| Smoking Status, n(%)      |           |         |         |
| Never                      | 3231 (71.0) | 1346 (60.4) | 563 (47.5) | <0.001  |
| Former                     | 516 (11.3)  | 353 (15.8)  | 244 (20.6)  |
| Current                    | 803 (17.7)  | 530 (23.8)  | 378 (31.9)  |
| Physical activity, MET-h/week | 23.25 ± 0.22 | 22.85 ± 0.32 | 22.52 ± 0.44 | 0.267   |
| AST                        | 25.91 ± 0.12 | 29.31 ± 0.38 | 35.99 ± 0.78 | <0.001  |
| ALT                        | 21.44 ± 0.15 | 30.26 ± 0.55 | 43.20 ± 1.45 | <0.001  |
| γ-GT                       | 16.38 ± 0.16 | 33.31 ± 0.73 | 74.41 ± 3.60 | <0.001  |
| Comorbidity, n(%)         |           |         |         |
| Hypertension               | 1310 (28.9) | 1107 (49.7) | 716 (60.4) | <0.001  |
| Diabetes mellitus          | 228 (5.0)  | 255 (11.4)  | 200 (16.9)  | <0.001  |
| Hyperlipidemia             | 1668 (36.7) | 1367 (61.3) | 859 (72.5) | <0.001  |
| Coronary artery disease    | 23 (0.51)  | 29 (1.3)   | 13 (1.1)   | 0.001   |
| Cancer                     | 59 (1.3)   | 15 (0.7)   | 12 (1.0)   | 0.064   |

FLI: fatty liver index. Values are presented as mean ± standard error.

3.2. Incidence and Hazard Ratios of Stroke According to the FLI Group

Table 2 shows the risk of stroke incidence according to the baseline FLI group. Around 1.67% (76/4550) of the non-NAFLD, 2.51% (56/2229) of the intermediate, and 3.03% (36/1185) of the NAFLD group developed stroke. The risk of developing stroke was higher in the NAFLD group (HR = 1.92, 95% CI = 1.29–2.85) than in the intermediate (HR = 1.53, 95% CI = 1.08–2.16) and non-NAFLD group (HR = 1) in the non-adjusted model. With the FLI < 30 group as the reference, the hazard ratios for stroke incidence increased in both groups after adjusting for confounding variables. After adjustment for age and sex (Model 1), NAFLD was associated with an increased risk of developing stroke (HR = 1.64, 95% CI = 1.10–2.46). In Model 2 (adjustment for hypertension, diabetes mellitus, hyperlipidemia, cardiovascular disease, smoking, alcohol status, and BMI) and Model 3 (Model 2 with additional adjustment for MET, cancer, anti-hyperlipidemic drug use, and antihypertensive drug use), the HRs (95% CI) for stroke incidence in the NAFLD group was 1.97 (1.17–3.2) and 1.98 (1.17–3.34), respectively, compared to that in the non-NAFLD group (p for trend < 0.001).
Table 2. Hazard ratio (95% confidence interval) for the incident of stroke according to the FLI groups.

| FLI            | <30 (n = 4550) | 30–59.9 (n = 2229) | ≥60 (n = 1185) | p-Value |
|---------------|----------------|--------------------|----------------|---------|
| Incident stroke case (n, %) | 76 (1.67) | 56 (2.51) | 36 (3.03) | 0.0004 |
| Crude Hazard ratio | 1.00 | 1.53 (1.08–2.16) | 1.92 (1.29–2.85) | 0.0025 |
| Model 1       | 1.00 | 1.31 (0.92–1.86) | 1.64 (1.10–2.46) | <0.001 |
| Model 2       | 1.00 | 1.42 (0.95–2.14) | 1.97 (1.17–3.32) | <0.001 |
| Model 3       | 1.00 | 1.41 (0.94–2.21) | 1.98 (1.17–3.34) | <0.001 |

Model 1: sex, age. Model 2: model 1 + hypertension, diabetes mellitus, hyperlipidemia, cardiovascular disease, smoking and alcohol status, and body mass index. Model 3: model 2 + metabolic equivalent of task, cancer, hyperlipidemia drug, and antihypertension drug. Estimated from Cox’s proportional hazard regression model. FLI: fatty liver index.

Figure 2 showed the cumulative incidence of stroke in each FLI group. The incidence rate and HRs of stroke were adjusted for age, sex, hypertension, diabetes mellitus, hyperlipidemia, cardiovascular disease, smoking and alcohol status, BMI, MET, cancer, anti-hyperlipidemic drug use, antihypertensive drug use, AST, ALT, and GGT.

Figure 2. Adjusted cumulative hazard curves for the incidence of cerebrovascular diseases according to the FLI group. Adjusted for age, sex, hypertension, diabetes mellitus, hyperlipidemia, cardiovascular disease, smoking and alcohol status, BMI, MET, cancer, anti-hyperlipidemic drug use, antihypertension drug, aspartate aminotransferase (AST), alanine aminotransferase (ALT), γ-glutamyl transpeptidase (GTP). Estimated by Cox's proportional hazard regression.

3.3. Incidence and Hazard Ratios of Stroke According to AST, ALT, and GGT

Figure 3 shows the HR for stroke by quartiles of AST, ALT, and GGT levels. In the analysis of the crude to fully adjusted model (Model 3), the highest quartile was not associated with an increased risk of developing stroke for AST (HR = 1.02, 95% CI = 0.66–1.58), ALT (HR = 1.09, 95% CI = 0.72–1.67), or GGT (HR = 1.00, 95% CI = 0.64–1.55) (Supplementary Table S1: Hazard ratio (95% confidence interval) for the incident of stroke according to the AST, ALT, and GGT groups.).
Figure 3. Hazard ratio (95% confidence interval) for the incident of cerebrovascular diseases according to the (A) AST, (B) ALT, and (C) gamma-glutamyltransferase (GGT). Model 1: sex, age. Model 2: model 1 + hypertension, diabetes mellitus, hyperlipidemia, cardiovascular disease, smoking and alcohol status, and body mass index. Model 3: model 2 + metabolic equivalent of task, cancer, hyperlipidemia drug, antihypertension drug, and the metabolic equivalent of task. Estimated from Cox’s proportional hazard regression model.

4. Discussions

This study showed the association between NAFLD, ALT, AST, GGT, and stroke incidence. NAFLD as defined by FLI increased the risk of developing future stroke. Stroke developed in 1.67%, 2.51%, and 3.03% in the non-NAFLD, intermediate, and NAFLD groups, respectively. Those with the highest FLI scores (>60) had an approximately two times higher risk of developing stroke (adjusted HR 1.98, 95% CI = 1.17–3.34) relative to the group with the lowest FLI (<30). In addition, AST, ALT, and GGT levels showed no meaningful statistical association.

A previous Korean study [21] revealed that NAFLD defined based on ultrasonography was associated with developing lacunar infarctions in non-obese patients. Furthermore, Wannamethee [22], in a larger prospective study in London, found that NAFLD with lower or moderate cardiovascular risk was independently correlated with a higher risk of ischemic stroke. In another meta-analysis of nine case-control and cohort studies, NAFLD was independently associated with 2.3 times higher risk of ischemic stroke [13].

Although many studies have reported positive associations between NAFLD and stroke, they differed according to age and sex. Kunutsor et al. suggested an inverse association between NAFLD and FLI in older participants (>50 years) and a positive association between NAFLD and FLI in younger participants [23]. In a case-cohort study, Alexander et al. showed that FLI > 60 was associated with a lower risk of stroke in men than in women [18].

Many studies regarding the association between NAFLD and severity or outcome of stroke, rather than the relationship between NAFLD and stroke incidence or risk have been conducted. Patients
with NAFLD had more severe strokes, as assessed using the National Institutes of Health Stroke Scale (NIHSS) at admission, and worse functional outcomes, as assessed using the modified Rankin Scale at discharge [12]. However, Baik et al. showed the paradoxical protective effect of NAFLD on functional outcomes and severity after ischemic strokes [16]. Patients with NAFLD had lower NIHSS scores and more favorable functional outcomes [16]. A recent study by Sheng et al. found no relationship between NAFLD and unfavorable outcomes after intracranial hemorrhage [15]. Another study by Li et al. demonstrated a positive association between NAFLD and severity and progression of brain stem infarction [24].

In our study, although NAFLD was associated with stroke development, liver biomarkers (AST, ALT, and GGT) were not associated with stroke development. In a case-cohort study, Alexander et al. showed the hazard ratio of stroke by quintiles of each biomarker, compared with the 1st quintile, and the hazard ratio per SD of each log-transformed marker. There was a strong inverse association of ALT with ischemic stroke in men, but not in women. Higher GGT was associated with reduced stroke risk in men, but no association in women [18]. In a small case-control study by Ying et al. [25], ALT and AST levels were independently associated with three times increased odds ratio for ischemic stroke. In the case-control EUROSTROKE study [26], performed in Finland, the Netherlands, and the United Kingdom, GGT levels were strongly associated with ischemic stroke risk in patients without type 2 diabetes mellitus. In a Korean prospective study, ALT was a predictor of intracerebral hemorrhage but not cerebral infarction [27]. A German case-cohort study found no association between overall stroke and ALT in a middle-aged population but found an association between ischemic stroke and GGT [28]. The British Women’s Heart and Health Study revealed that ALT levels were not associated with stroke in women [29].

The reason why there is a difference in the association with stroke between NAFLD defined by FLI and liver biomarkers is that NAFLD and liver biomarkers have different significances. NAFLD comprises a wide histological spectrum ranging from fat accumulation in hepatocytes without inflammation or fibrosis (simple hepatic steatosis) to hepatic steatosis with necroinflammatory elements (steatohepatitis) [30]. The presence of fibrosis and inflammation is termed non-alcoholic steatohepatitis, which may eventually progress to cirrhosis in up to 20% of patients [31]. Liver dysfunction caused by NAFLD can contribute to thrombotic vascular disease by affecting the synthesis of lipoproteins [32], coagulation proteins [33], and inflammation-related factors [34]. However, elevated liver enzymes do not suggest a correlation between the level of liver injury, fibrosis, or inflammation; therefore, elevated liver enzymes may not be related to the abnormal mechanisms of vasculopathy [35]. ALT is found in the cytosol of hepatocytes where it transfers amino groups, although the major site where AST is found in the mitochondria [36]. Amino group transfer from alanine to ketoglutarate is catalyzed by ALT. Even though ALT is mostly specific to the liver, it can be found in the blood during muscle injury or inflammation [37]. In addition, GGT is less specific to the liver and has been used as a marker of biliary disease and alcoholic intake [38]. Because of these differences, NAFLD as defined by FLI was identified as a potential risk factor for stroke in this study, but the liver index was inappropriate. FLI, which is obtained through TG and BMI, suggests that NAFLD is associated with whole-body obesity and aberration of lipid levels rather than liver disease only and is therefore also associated with cardio and cerebrovascular abnormalities [39,40].

The following are the key strengths of the present study. This is a well-characterized prospective study with a large cohort of participants; it is geographically dispersed in rural and urban areas, and a 12-year follow-up was conducted. Furthermore, it is the first population-based prospective study to explore the potential role of NAFLD in developing stroke in a healthy middle-aged population of Korea.

This study had some limitations. First, our study used a surrogate marker for NAFLD. The gold standard for the clinical diagnosis of NAFLD is liver biopsy, which is not appropriate for epidemiological studies. Although FLI compares well with ultrasound-based determination of fatty liver, it is less accurate than liver biopsy or magnetic resonance imaging for identifying and grading liver steatosis [41].
In support of its use, we saw strong correlations between FLI and components of metabolic syndrome and a higher prevalence of NAFLD in men than in women, which were similar to findings that used an imaging-based NAFLD assessment [42,43]. Second, stroke was not divided into ischemic and hemorrhagic strokes because the occurrence of a stroke was investigated using a questionnaire. Because hemorrhagic strokes leave severe dysfunction, the participants who remained in the cohort and were able to be monitored would have suffered an ischemic stroke. Third, recall bias may have occurred because the KoGES data were based on questionnaires.

5. Conclusions

This study demonstrated that the risk of stroke incidence gradually increased with an increase in FLI. Individuals with NAFLD should be properly counseled and monitored for risk for stroke.

Supplementary Materials: The following are available online at http://www.mdpi.com/1660-4601/17/24/9568/s1, Table S1: Hazard ratio (95% confidence interval) for the incident of stroke according to the AST, ALT, and GGT groups.

Author Contributions: Conceptualization, S.J.A.; methodology, M.-H.J.; software, Y.-P.H.; validation, Y.-J.Y.; formal analysis, Y.-J.Y.; investigation, S.J.A.; resources, S.-H.J.; data curation, Y.-J.Y.; writing—original draft preparation, M.-H.J.; writing—review and editing, S.J.A.; visualization, S.-H.J.; supervision, Y.I.K.; project administration, M.-H.J.; funding acquisition, None. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Acknowledgments: Data in this study were from the Korean Genome and Epidemiology Study (KoGES; 4851-302), National Research Institute of Health, Centers for Disease Control and Prevention, Ministry for Health and Welfare, Korea.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Benjamin, E.J.; Blaha, M.J.; Chiuve, S.E.; Cushman, M.; Das, S.R.; Deo, R.; de Ferranti, S.D.; Floyd, J.; Fornage, M.; Gillespie, C.; et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation 2017, 135, e146–e603. [CrossRef] [PubMed]
2. Feigin, V.L.; Roth, G.A.; Naghavi, M.; Parmar, P.; Krishnamurthi, R.; Chugh, S.; Mensah, G.A.; Norrving, B.; Shiue, I.; Ng, M.; et al. Global burden of stroke and risk factors in 188 countries, during 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet Neurol. 2016, 15, 913–924. [CrossRef] [PubMed]
3. Venketasubramanian, N.; Yoon, B.W.; Pandian, J.; Navarro, J.C. Stroke Epidemiology in South, East, and South-East Asia: A Review. J. Stroke 2017, 19, 286–294. [CrossRef] [PubMed]
4. Jeong, H.Y.; Jung, K.H.; Mo, H.; Lee, C.H.; Kim, T.J.; Park, J.M.; Oh, M.; Lee, J.S.; Kim, B.J.; Kim, J.T.; et al. Characteristics and management of stroke in Korea: 2014–2018 data from Korean Stroke Registry. Int. J. Stroke 2019. [CrossRef]
5. Hong, K.S.; Bang, O.Y.; Kang, D.W.; Yu, K.H.; Bae, H.J.; Lee, J.S.; Heo, J.H.; Kwon, S.U.; Oh, C.W.; Lee, B.C.; et al. Stroke statistics in Korea: Part I. Epidemiology and risk factors: A report from the korean stroke society and clinical research center for stroke. J. Stroke 2013, 15, 2–20. [CrossRef]
6. Hopewell, J.C.; Clarke, R. Emerging Risk Factors for Stroke: What Have We Learned From Mendelian Randomization Studies? Stroke 2016, 47, 1673–1678. [CrossRef]
7. An, S.J.; Kim, T.J.; Yoon, B.W. Epidemiology, Risk Factors, and Clinical Features of Intracerebral Hemorrhage: An Update. J. Stroke 2017, 19, 3–10. [CrossRef]
8. Arboix, A. Cardiovascular risk factors for acute stroke: Risk profiles in the different subtypes of ischemic stroke. World J. Clin. Cases 2015, 3, 418–429. [CrossRef]
9. Alkagiet, S.; Papagiannis, A.; Tziomalos, K. Associations between nonalcoholic fatty liver disease and ischemic stroke. World J. Hepatol. 2018, 10, 474–478. [CrossRef]
10. Bouziana, S.D.; Tziomalos, K. Inhibition of apoptosis in the management of nonalcoholic fatty liver disease. World J. Gastrointest. Pharmacol. Ther. 2013, 4, 4–8. [CrossRef]
11. Papagianni, M.; Tziomalos, K. Non-alcoholic fatty liver disease: An emerging predictor of stroke risk, severity and outcome. Eur. J. Neurol. 2018, 25, 610–611. [CrossRef] [PubMed]
12. Abdeldyem, S.M.; Goda, T.; Khodeir, S.A.; Abou Saif, S.; Abd-Elsalam, S. Nonalcoholic fatty liver disease in patients with acute ischemic stroke is associated with more severe stroke and worse outcome. J. Clin. Lipidol. 2017, 11, 915–919. [CrossRef] [PubMed]

13. Hu, J.; Xu, Y.; He, Z.; Zhang, H.; Lian, X.; Zhu, T.; Liang, C.; Li, J. Increased risk of cerebrovascular accident related to non-alcoholic fatty liver disease: A meta-analysis. Oncotarget 2018, 9, 2752–2760. [CrossRef] [PubMed]

14. Parikh, N.S.; VanWagner, L.B.; Elkind, M.S.V.; Gutierrez, J. Association between nonalcoholic fatty liver disease with advanced fibrosis and stroke. J. Neurol. Sci. 2019, 407, 116524. [CrossRef] [PubMed]

15. Tu, S.; Zhao, R.; Fang, H.; Wang, L.; Shao, A.; Sheng, J. Association between Non-Alcoholic Fatty Liver Disease and Intracerebral Hemorrhage. Cell Transplant. 2019, 28, 1033–1038. [CrossRef] [PubMed]

16. Baik, M.; Kim, S.U.; Nam, H.S.; Heo, J.H.; Kim, Y.D. The Paradoxical Protective Effect of Liver Steatosis on Severity and Functional Outcome of Ischemic Stroke. Front. Neurol. 2019, 10, 375. [CrossRef]

17. An, S.J.; Jung, M.H.; Ihm, S.H.; Yang, Y.J.; Yoon, H.J. Effect of physical activity on the cardiometabolic profiles of non-obese and obese subjects: Results from the Korea National Health and Nutritional Examination Survey. PLoS ONE 2019, 14, e0208189. [CrossRef]

18. Alexander, K.S.; Zakai, N.A.; Lidoﬁsky, S.D.; Callas, P.W.; Judd, S.E.; Tracy, R.P.; Cushman, M. Non-alcoholic fatty liver disease, liver biomarkers and stroke risk: The Reasons for Geographic and Racial Differences in Stroke cohort. PLoS ONE 2018, 13, e0194153. [CrossRef]

19. Kim, Y.; Han, B.G.; KoGES group. Cohort Proﬁle: The Korean Genome and Epidemiology Study (KoGES) Consortium. Int. J. Epidemiol. 2017, 46, e20. [CrossRef]

20. Bedogni, G.; Bellentani, S.; Miglioli, L.; Masutti, F.; Passalacqua, M.; Castiglione, A.; Tiritelli, C. The Fatty Liver Index: A simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006, 6, 33. [CrossRef]

21. Kwak, M.S.; Kim, K.W.; Seo, H.; Chung, G.E.; Yim, J.Y.; Kim, D. Non-obese fatty liver disease is associated with lacunar infarct. Liver Int. 2018, 38, 1292–1299. [CrossRef] [PubMed]

22. Wannamethee, S.G.; Lennon, L.; Shaper, A.G. The value of gamma-glutamyltransferase in cardiovascular risk prediction in men without diagnosed cardiovascular disease or diabetes. Atherosclerosis 2008, 201, 168–175. [CrossRef] [PubMed]

23. Kunutsor, S.K.; Bakker, S.J.L.; Blokzijl, H.; Dullaart, R.P.F. Associations of the fatty liver and hepatic steatosis with stroke: Intermolecular relationship with age. Clin. Chim. Acta 2017, 466, 54–60. [CrossRef] [PubMed]

24. Li, H.; Hu, B.; Wei, L.; Zhou, L.; Zhang, L.; Lin, Y.; Qin, B.; Dai, Y.; Lu, Z. Non-alcoholic fatty liver disease is associated with stroke severity and progression of brainstem infarctions. Eur. J. Neurol. 2018, 25, 577-e34. [CrossRef]

25. Ying, Y.; Saposnik, G.; Vermeulen, M.J.; Leung, A.; Ray, J.G. Nonalcoholic fatty liver disease and acute ischemic stroke. Epidemiology 2012, 23, 129–130. [CrossRef]

26. Bols, M.L.; Salonen, J.T.; Elwood, P.C.; Nikitin, Y.; Freire de Concalves, A.; Inzitari, D.; Sivenius, J.; Trichopoulou, A.; Tuomilehto, J.; Koudstaal, P.J.; et al. Gamma-glutamyltransferase and risk of stroke: The EUROSTROKE project. J. Epidemiol. Community Health 2002, 56 (Suppl. 1), i25–i29. [CrossRef]

27. Kim, H.C.; Kang, D.R.; Nam, C.M.; Hur, N.W.; Shim, J.S.; Jee, S.H.; Suh, I. Elevated serum aminotransferase level as a predictor of intracerebral hemorrhage: Korea medical insurance corporation study. Stroke 2005, 36, 1642–1647. [CrossRef]

28. Weikert, C.; Drogan, D.; di Giuseppe, R.; Fritsche, A.; Buijsse, B.; Nothlings, U.; Willich, S.N.; Berger, K.; Boeing, H. Liver enzymes and stroke risk in middle-aged German adults. Atherosclerosis 2013, 228, 508–514. [CrossRef]

29. Fraser, A.; Harris, R.; Sattar, N.; Ebrahim, S.; Smith, G.D.; Lawlor, D.A. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: Analysis of the British Women’s Heart and Health Study and Meta-Analysis. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 2729–2735. [CrossRef]

30. Matteoni, C.A.; Younossi, Z.M.; Gramlich, T.; Boparai, N.; Liu, Y.C.; McCullough, A.J. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999, 116, 1413–1419. [CrossRef]

31. Caldwell, S.H.; Oelsner, D.H.; Iezzoni, J.C.; Hespenheide, E.E.; Battle, E.H.; Driscoll, C.J. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease. Hepatology 1999, 29, 664–669. [CrossRef] [PubMed]
32. Dixon, J.L.; Ginsberg, H.N. Hepatic synthesis of lipoproteins and apolipoproteins. *Semin. Liver Dis.* 1992, 12, 364–372. [CrossRef]

33. Lisman, T.; Porte, R.J. Pathogenesis, prevention, and management of bleeding and thrombosis in patients with liver diseases. *Res. Pract. Thromb. Haemost.* 2017, 1, 150–161. [CrossRef] [PubMed]

34. Moshage, H. Cytokines and the hepatic acute phase response. *J. Pathol.* 1997, 181, 257–266. [CrossRef]

35. Angulo, P.; Keach, J.C.; Batts, K.P.; Lindor, K.D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. *Hepatology* 1999, 30, 1356–1362. [CrossRef] [PubMed]

36. Rej, R. Aspartate aminotransferase activity and isoenzyme proportions in human liver tissues. *Clin. Chem.* 1978, 24, 1971–1979. [CrossRef]

37. Nathwani, R.A.; Pais, S.; Reynolds, T.B.; Kaplowitz, N. Serum alanine aminotransferase in skeletal muscle diseases. *Hepatology* 2005, 41, 380–382. [CrossRef]

38. Whitfield, J.B. Gamma glutamyl transferase. *Crit. Rev. Clin. Lab. Sci.* 2001, 38, 263–355. [CrossRef]

39. Rhoads, G.G.; Feinleib, M. Serum triglyceride and risk of coronary heart disease, stroke, and total mortality in Japanese-American men. *Arteriosclerosis* 1983, 3, 316–322. [CrossRef]

40. Salonen, J.T.; Puska, P. Relation of serum cholesterol and triglycerides to the risk of acute myocardial infarction, cerebral stroke and death in eastern Finnish male population. *Int. J. Epidemiol.* 1983, 12, 26–31. [CrossRef]

41. Machado, M.V.; Cortez-Pinto, H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. *J. Hepatol.* 2013, 58, 1007–1019. [CrossRef] [PubMed]

42. Gastaldelli, A.; Kozakova, M.; Hojlund, K.; Flyvbjerg, A.; Favuzzi, A.; Mitrakou, A.; Balkau, B.; Investigators, R. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. *Hepatology* 2009, 49, 1537–1544. [CrossRef] [PubMed]

43. Lazo, M.; Clark, J.M. The epidemiology of nonalcoholic fatty liver disease: A global perspective. *Semin. Liver Dis.* 2008, 28, 339–350. [CrossRef] [PubMed]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).